Effects of azelnidipine on uric acid metabolism in patients with essential hypertension
Effects of azelnidipine on uric acid metabolism in patients with essential hypertension
复制标题
DOI：
10.3109/10641963.2013.846359
复制
发表时间：
2014-01-01
影响因子：
12.3
通讯作者：
Hisatome, Ichiro
中科院分区：
文献类型：
--
作者：
Miyazaki, Satoshi;Hamada, Toshihiro;Hisatome, Ichiro
目的：目的：观察长效钙通道阻滞剂阿折地平对高血压患者尿酸代谢的影响。72例患者中有22例患者将不同的CCB转换为阿折地平。结果：阿折地平能显著降低收缩压、舒张压和心率，并能显著降低血压和心率，与对照组比较，差异有统计学意义（P <0.05）。降低血清尿酸水平和尿尿酸/肌酐比值（Uur/Ucr），但不影响尿酸清除率/肌酐清除率比值（Cur/Ccr）。在Uur/Ucr >= 0.5或>= 0.34的患者中，阿折地平降低了Uur/Ucr和Cur/Ccr，但在Uur/Ucr = 6.0 mg/dL的女性患者中，阿折地平没有改变这些清除参数。它并没有改变这些参数在正常尿酸血症患者血清尿酸水平
Purpose: To examine effects of a long-acting calcium channel blocker (CCB) azelnidipine on uric acid metabolism in hypertensive patients.Methods: Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg. In 22 cases out of the 72 patients, a different CCB was switched to azelnidipine. Blood pressure was measured and biochemical parameters of blood and urine were evaluated before and 2-3 months after the administration.Results: Azelnidipine significantly decreased both systolic and diastolic blood pressure and the heart rate. It decreased both serum urate levels and the urinary uric acid to creatinine ratio (Uur/Ucr), but did not affect the uric acid clearance to creatinine clearance ratio (Cur/Ccr). Azelnidipine decreased both Uur/Ucr and Cur/Ccr in patients with Uur/Ucr >= 0.5 or >= 0.34, although it did not change these clearance parameters in patients with Uur/Ucr = 6.0 mg/dL in females. It did not change these parameters in normouricemic patients with serum urate levels